Contact: Richard EisenstadtChief Financial OfficerNeos Therapeutics(972) email@example.comSarah McCabeStern Investor Relations, Inc.(212) firstname.lastname@example.org
DALLAS and FORT WORTH, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 3:45 p.m. ET in New York, NY. A live webcast of the presentation will be available on the Investor Relations page of the company's website at http://investors.neostx.com/. About Neos Therapeutics Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD, is the first approved product using the Company's XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex® 1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold. 1Tussionex® is a registered trademark of the UCB Group of Companies.